Technology Networks: Driving Drug Discovery Success With Synthetic Biology and NGS

Last month, A-Alpha Bio's CEO David Younger had a Q&A session with Technology Networks's Laura Elizabeth Lansdowne to discuss how the company's ability to harness synthetic biology and next generation sequencing can identify millions of protein-protein interactions.

Recent Posts

See All

A-Alpha Bio Secures $20M Series A Financing!

This morning we announced that we have closed a $20M Series A Financing Round to dramatically expand our capabilities and throughput! The round was led by Madrona Venture Group, our partner since the